, Volume 231, Issue 4, pp 639–649

Tamoxifen use for the management of mania: a review of current preclinical evidence

  • Fernanda Armani
  • Monica Levy Andersen
  • José Carlos Fernandes Galduróz



Preliminary data on the efficacy of tamoxifen in reducing manic symptoms of bipolar disorder (BD) suggest that this agent may be a potential treatment for the management of this psychiatric disorder. However, the antimanic properties of tamoxifen have not been fully elucidated, hampering the development and/or use of mood-stabilising drugs that may share its same therapeutic mechanisms of action. Notably, we may gain a greater understanding of the neurobiological and therapeutic properties of tamoxifen by using suitable animal models of mania.


Here, we review the preclinical studies that have evaluated the effects of tamoxifen to provide an overview of the current progress in our understanding of its antimanic actions, highlighting the critical role of protein kinase C (PKC) as a therapeutic target for the treatment of BD.


To date, this field has struggled to make significant progress, and the organisation of an explicit battery of tests is a valuable tool for assessing a number of prominent facets of BD, which may provide a greater understanding of the entire scope of this disease.


Bipolar disorder Mania Tamoxifen Protein kinase C (PKC) Animal models Antimanic treatment 


  1. Abrial E, Etievant A, Bétry C, Scarna H, Lucas G, Haddjeri N, Lambás-Señas L (2012) Protein kinase C regulates mood-related behaviors and adult hippocampal cell proliferation in rats. Prog Neuropsychopharmacol Biol Psychiatry 43C:40–48Google Scholar
  2. Aksoy E, Goldman M, Willems F (2004) Protein kinase C epsilon: a new target to control inflammation and immune-mediated disorders. Int J Biochem Cell Biol 36:183–8PubMedGoogle Scholar
  3. Alda M, Hajek T, Calkin C, O'Donovan C (2009) Treatment of bipolar disorder: new perspectives. Ann Med 41:186–96PubMedGoogle Scholar
  4. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  5. Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Ahmadi-Abhari SA, Sadeghi M, Tabrizi M, Akhondzadeh S (2011) Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 129:327–31PubMedGoogle Scholar
  6. Andreatini R (2002) A importância dos modelos animais em psiquiatria. Rev Bras Psiquiatr 24:164Google Scholar
  7. Andreatini R, Lacerda R, Vital M (2006) Modelos animais em psicofarmacologia. In: Almeida R (ed) Psicofarmacologia: fundamentos práticos. Guanabara-Koogan, Rio de Janeiro, pp 53–61Google Scholar
  8. Armani F, Andersen ML, Andreatini R, Frussa-Filho R, Tufik S, Galduróz JC (2012) Successful combined therapy with tamoxifen and lithium in a paradoxical sleep deprivation-induced mania model. CNS Neurosci Ther 18:119–25PubMedGoogle Scholar
  9. Barbini B, Bertelli S, Colombo C, Smeraldi E (1996) Sleep loss, a possible factor in augmenting manic episode. Psychiatry Res 65:121–5PubMedGoogle Scholar
  10. Basu A, Pal D (2010) Two faces of protein kinase Cδ: the contrasting roles of PKCδ in cell survival and cell death. Sci World J 10:2272–84Google Scholar
  11. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, Schulze TG, Cichon S, Rietschel M, Nothen MM, Georgi A, Schumacher J, Schwarz M, Abou Jamra R, Hofels S, Propping P, Satagopan J, Detera-Wadleigh SD, Hardy J, McMahon FJ (2008) A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 13:197–207PubMedCentralPubMedGoogle Scholar
  12. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK (2000) A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 57:95–7PubMedGoogle Scholar
  13. Becker JB, Snyder PJ, Miller MM, Westgate SA, Jenuwine MJ (1987) The influence of estrous cycle and intrastriatal estradiol on sensorimotor performance in the female rat. Pharmacol Biochem Behav 27:53–9PubMedGoogle Scholar
  14. Benedetti F, Fresi F, Maccioni P, Smeraldi E (2008) Behavioural sensitization to repeated sleep deprivation in a mice model of mania. Behav Brain Res 187:221–7PubMedGoogle Scholar
  15. Benes FM, Kwok EW, Vincent SL, Todtenkopf MS (1998) A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry 44:88–97PubMedGoogle Scholar
  16. Birnbaum SG, Yuan PX, Wang M, Vijayraghavan S, Bloom AK, Davis DJ, Gobeske KT, Sweatt JD, Manji HK, Arnsten AF (2004) Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 306:882–4PubMedGoogle Scholar
  17. Bitran JA, Potter WZ, Manji HK, Gusovsky F (1990) Chronic Li+ attenuates agonist- and phorbol ester-mediated Na+/H+ antiporter activity in HL-60 cells. Eur J Pharmacol 188:193–202Google Scholar
  18. Browman KE, Kantor L, Richardson S, Badiani A, Robinson TE, Gnegy ME (1998) Injection of the protein kinase C inhibitor Ro31-8220 into the nucleus accumbens attenuates the acute response to amphetamine: tissue and behavioral studies. Brain Res 814:112–9PubMedGoogle Scholar
  19. Burdick KE, Braga RJ, Goldberg JF, Malhotra AK (2007) Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy. CNS Drugs 21:971–81PubMedGoogle Scholar
  20. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A, Cano J, Brundin P, Englund E, Venero JL, Joseph B (2011) Caspase signalling controls microglia activation and neurotoxicity. Nature 472:319–24PubMedGoogle Scholar
  21. Burrows KB, Gudelsky G, Yamamoto BK (2000) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur J Pharmacol 398:11–8PubMedGoogle Scholar
  22. Cadet JL, Jayanthi S, Deng X (2005) Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review. Neurotox Res 8:199–206PubMedGoogle Scholar
  23. Calabrese B, Halpain S (2005) Essential role for the PKC target MARCKS in maintaining dendritic spine morphology. Neuron 48:77–90PubMedGoogle Scholar
  24. Cardoso CM, Almeida LM, Custódio JB (2002) 4-Hydroxytamoxifen is a potent inhibitor of the mitochondrial permeability transition. Mitochondrion 1:485–95PubMedGoogle Scholar
  25. Cardoso CM, Almeida LM, Custódio JB (2004) Protection of tamoxifen against oxidation of mitochondrial thiols and NAD(P)H underlying the permeability transition induced by prooxidants. Chem Biol Interact 148:149–61PubMedGoogle Scholar
  26. Casabona G (1997) Intracellular signal modulation: a pivotal role for protein kinase C. Prog Neuro-Psychopharmacol Biol Psychiatry 21:407–25Google Scholar
  27. Cechinel-Recco K, Valvassori SS, Varela RB, Resende WR, Arent CO, Vitto MF, Luz G, de Souza CT, Quevedo J (2012) Lithium and tamoxifen modulate cellular plasticity cascades in animal model of mania. J Psychopharmacol 26:1594–604PubMedGoogle Scholar
  28. Cervo L, Mukherjee S, Bertaglia A, Samanin R (1997) Protein kinases A and C are involved in the mechanisms underlying consolidation of cocaine place conditioning. Brain Res 775:30–6PubMedGoogle Scholar
  29. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ (1994) Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 63:2361–4PubMedGoogle Scholar
  30. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GW, Mochly-Rosen D (2001) Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U S A 98:11114–9PubMedCentralPubMedGoogle Scholar
  31. Churchill E, Budas G, Vallentin A, Koyanagi T, Mochly-Rosen D (2008) PKC isozymes in chronic cardiac disease: possible therapeutic targets? Annu Rev Pharmacol Toxicol 48:569–99PubMedGoogle Scholar
  32. Colombo C, Benedetti F, Barbini B, Campori E, Smeraldi E (1999) Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psychiatry Res 86:267–70PubMedGoogle Scholar
  33. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo ML, Masri L, Law RE, Weiss MH (1996) Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 2:619–22PubMedGoogle Scholar
  34. Craske ML, Fivaz M, Batada NN, Meyer T (2005) Spines and neurite branches function as geometric attractors that enhance protein kinase C action. J Cell Biol 170:1147–58PubMedGoogle Scholar
  35. Das Evcimen N, King GL (2007) The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 55:498–510PubMedGoogle Scholar
  36. Dempsey EC, Cool CD, Littler CM (2007) Lung disease and PKCs. Pharmacol Res 55:545–59PubMedGoogle Scholar
  37. Dencker D, Husum H (2010) Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav Brain Res 207:78–83PubMedGoogle Scholar
  38. Deng Y, Kohlwein SD, Mannella CA (2002) Fasting induces cyanide-resistant respiration and oxidative stress in the amoeba Chaos carolinensis: implications for the cubic structural transition in mitochondrial membranes. Protoplasma 219:160–7PubMedGoogle Scholar
  39. DiazGranados N, Zarate CA Jr (2008) A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr Psychiatry Rep 10:510–9PubMedCentralPubMedGoogle Scholar
  40. Einat H (2006) Modelling facets of mania—new directions related to the notion of endophenotypes. J Psychopharmacol 20:714–22PubMedGoogle Scholar
  41. Einat H (2007a) Different behaviors and different strains: potential new ways to model bipolar disorder. Neurosci Biobehav Rev 31:850–7PubMedGoogle Scholar
  42. Einat H (2007b) Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease. Behav Genet 37:244–55PubMedGoogle Scholar
  43. Einat H, Chen G, Manji H (2004) Possible involvement of protein kinase C in the pathophysiology and treatment of bipolar disorder. Harefuah 143(420–5):462Google Scholar
  44. Einat H, Yuan P, Szabo ST, Dogra S, Manji HK (2007) Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 55:123–31PubMedGoogle Scholar
  45. Ferreira JC, Koyanagi T, Palaniyandi SS, Fajardo G, Churchill EN, Budas G, Disatnik MH, Bernstein D, Brum PC, Mochly-Rosen D (2011) Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy. J Mol Cell Cardiol 51:980–7PubMedCentralPubMedGoogle Scholar
  46. Fibiger HC (1995) Neurobiology of depression: focus on dopamine. In: Gessa GL, Fratta W, Pani L, Serra G (eds) Depression and mania: from neurobiology to treatment. Raven, New York, pp 1–18Google Scholar
  47. Flaisher-Grinberg S, Overgaard S, Einat H (2009) Attenuation of high sweet solution preference by mood stabilizers: a possible mouse model for the increased reward-seeking domain of mania. J Neurosci Methods 177:44–50PubMedGoogle Scholar
  48. Frey BN, Valvassori SS, Reus GZ, Martins MR, Petronilho FC, Bardini K, Dal-Pizzol F, Kapczinski F, Quevedo J (2006) Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 31:326–32PubMedCentralPubMedGoogle Scholar
  49. Friedman E, Hoau Yan W, Levinson D, Connell TA, Singh H (1993) Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 33:520–5PubMedGoogle Scholar
  50. Garrido JL, Godoy JA, Alvarez A, Bronfman M, Inestrosa NC (2002) Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J 16:1982–4PubMedGoogle Scholar
  51. Geraldes P, King GL (2010) Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106:1319–31PubMedCentralPubMedGoogle Scholar
  52. Gessa GL, Pani L, Fadda P, Fratta W (1995) Sleep deprivation in the rat: an animal model of mania. Eur Neuropsychopharmacol 5(Suppl):89–93PubMedGoogle Scholar
  53. Geyer MA (2008) Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox Res 14:71–8PubMedCentralPubMedGoogle Scholar
  54. Giambalvo CT (1992a) Protein kinase C and dopamine transport—1. Effects of amphetamine in vivo. Neuropharmacology 31:1201–10PubMedGoogle Scholar
  55. Giambalvo CT (1992b) Protein kinase C and dopamine transport—2. Effects of amphetamine in vitro. Neuropharmacology 31:1211–22PubMedGoogle Scholar
  56. Gitlin M (2006) Treatment-resistant bipolar disorder. Mol Psychiatry 11:227–40PubMedGoogle Scholar
  57. Gnegy ME, Hong P, Ferrell ST (1993) Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine. Brain Res Mol Brain Res 20:289–98PubMedGoogle Scholar
  58. Goodwin FK, Jamison KR (2007) Manic-depressive illness: bipolar disorders and recurrent depression, 2nd edn. Oxford University Press, LondonGoogle Scholar
  59. Gould TD, Einat H (2007) Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci Biobehav Rev 31:825–31PubMedCentralPubMedGoogle Scholar
  60. Hahn CG, Friedman E (1999) Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord 1:81–6PubMedGoogle Scholar
  61. Huang KP (1990) Role of protein kinase C in cellular regulation. Biofactors 2:171–8PubMedGoogle Scholar
  62. Inagaki K, Churchill E, Mochly-Rosen D (2006) Epsilon protein kinase C as a potential therapeutic target for the ischemic heart. Cardiovasc Res 70:222–30PubMedGoogle Scholar
  63. Jordan VC (1992) The role of tamoxifen in the treatment and prevention of breast cancer. Curr Probl Cancer 16:129–76PubMedGoogle Scholar
  64. Jordan VC (2003) Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2:205–13PubMedGoogle Scholar
  65. Kantor L, Gnegy ME (1998) Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther 284:592–8PubMedGoogle Scholar
  66. Kara NZ, Einat H (2013) Rodent models for mania: practical approaches. Cell Tissue Res 354:191–201PubMedGoogle Scholar
  67. Karn A, Jha AK, Shrestha S, Acharya B, Poudel S, Bhandari RB (2010) Tamoxifen for breast cancer. JNMA J Nepal Med Assoc 49:62–7PubMedGoogle Scholar
  68. Kato T (2008) Molecular neurobiology of bipolar disorder: a disease of 'mood-stabilizing neurons'?. Trends Neurosci 31:495–503Google Scholar
  69. Kimelberg HK, Feustel PJ, Jin Y, Paquette J, Boulos A, Keller RW, Tranmer BI (2000) Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion. Neuroreport 11:2675–9PubMedGoogle Scholar
  70. Krishnan KR (2005) Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 67:1–8PubMedGoogle Scholar
  71. Kulkarni J, Garland KA, Scaffidi A, Headey B, Anderson R, de Castella A, Fitzgerald P, Davis SR (2006) A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 31:543–7PubMedGoogle Scholar
  72. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N (2002) Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20:171–5PubMedGoogle Scholar
  73. Kupfer DJ (2005) The increasing medical burden in bipolar disorder. Jama 293:2528–30PubMedGoogle Scholar
  74. Kurita M, Nishino S, Ohtomo K, Rai M, Shirakawa H, Mashiko H, Niwa S, Nakahata N (2007) Sodium valproate at therapeutic concentrations changes Ca2+ response accompanied with its weak inhibition of protein kinase C in human astrocytoma cells. Prog Neuropsychopharmacol Biol Psychiatry 31:600–4Google Scholar
  75. Kuruvilla A, Uretsky NJ (1981) Effect of sodium valproate on motor function regulated by the activation of GABA receptors. Psychopharmacol (Berl) 72:167–72Google Scholar
  76. Lenox RH, Watson DG, Patel J, Ellis J (1992) Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 570:333–40PubMedGoogle Scholar
  77. Lerer B, Globus M, Brik E, Hamburger R, Belmaker RH (1984) Effect of treatment and withdrawal from chronic lithium in rats on stimulant-induced responses. Neuropsychobiology 11:28–32PubMedGoogle Scholar
  78. MacDonald JF, Kotecha SA, Lu WY, Jackson MF (2001) Convergence of PKC-dependent kinase signal cascades on NMDA receptors. Curr Drug Targets 2:299–312PubMedGoogle Scholar
  79. Machado-Vieira R, Kapczinski F, Soares JC (2004) Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 28:209–24PubMedGoogle Scholar
  80. Machado-Vieira R, Salvadore G, DiazGranados N, Ibrahim L, Latov D, Wheeler-Castillo C, Baumann J, Henter ID, Zarate CA (2010) New therapeutic targets for mood disorders. Sci World J 10:713–26Google Scholar
  81. Mackay HJ, Twelves CJ (2007) Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 7:554–62PubMedGoogle Scholar
  82. Maioli E, Valacchi G (2010) Rottlerin: bases for a possible usage in psoriasis. Curr Drug Metab 11:425–30PubMedGoogle Scholar
  83. Malkesman O, Austin DR, Chen G, Manji HK (2009) Reverse translational strategies for developing animal models of bipolar disorder. Dis Model Mech 2:238–45PubMedCentralPubMedGoogle Scholar
  84. Mamelak M (1978) An amphetamine model of manic depressive illness. Int Pharmacopsychiatry 13:193–208PubMedGoogle Scholar
  85. Manji HK, Bersudsky Y, Chen G, Belmaker RH, Potter WZ (1996) Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositol. Neuropsychopharmacol 15:370–81Google Scholar
  86. Manji H (2008) The role of synaptic and cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Actas Esp Psiquiatr 36(Suppl 1):1–2Google Scholar
  87. Manji HK, Lenox RH (2000) Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 48:518–30PubMedGoogle Scholar
  88. Manji HK, Etcheberrigaray R, Chen G, Olds JL (1993) Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J Neurochem 61:2303–10PubMedGoogle Scholar
  89. Mastronardi L, Puzzilli F, Couldwell WT, Farah JO, Lunardi P (1998) Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neurooncol 38:59–68PubMedGoogle Scholar
  90. Meinhard N, Kessing LV, Vinberg M (2013) The role of estrogen in bipolar disorder, a review. Nord J Psychiatry.Google Scholar
  91. Mellor H, Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332(Pt 2):281–92PubMedGoogle Scholar
  92. Mochly-Rosen D, Das K, Grimes KV (2012) Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 11:937–57PubMedCentralPubMedGoogle Scholar
  93. Moretti M, Valvassori SS, Steckert AV, Rochi N, Benedet J, Scaini G, Kapczinski F, Streck EL, Zugno AI, Quevedo J (2011) Tamoxifen effects on respiratory chain complexes and creatine kinase activities in an animal model of mania. Pharmacol Biochem Behav 98:304–10PubMedGoogle Scholar
  94. Morgan MA, Pfaff DW (2001) Effects of estrogen on activity and fear-related behaviors in mice. Horm Behav 40:472–82PubMedGoogle Scholar
  95. Morgan MA, Pfaff DW (2002) Estrogen's effects on activity, anxiety, and fear in two mouse strains. Behav Brain Res 132:85–93PubMedGoogle Scholar
  96. Morgan MA, Schulkin J, Pfaff DW (2004) Estrogens and non-reproductive behaviors related to activity and fear. Neurosci Biobehav Rev 28:55–63PubMedGoogle Scholar
  97. Murriel CL, Mochly-Rosen D (2003) Opposing roles of delta and epsilonPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery. Arch Biochem Biophys 420:246–54PubMedGoogle Scholar
  98. Nestler EJ, Hyman SE (2010) Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161–9PubMedCentralPubMedGoogle Scholar
  99. Newton AC (1995) Protein kinase C. Seeing two domains. Curr Biol 5:973–6PubMedGoogle Scholar
  100. Nierenberg AA (2010) A critical appraisal of treatments for bipolar disorder. Prim Care Companion J Clin Psychiatry 12:23–9PubMedCentralPubMedGoogle Scholar
  101. Nishizuka Y (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607–14PubMedGoogle Scholar
  102. Nishizuka Y, Nakamura S (1995) Lipid mediators and protein kinase C for intracellular signalling. Clin Exp Pharmacol Physiol Suppl 22:S202–3PubMedGoogle Scholar
  103. Nogues X (1997) Protein kinase C, learning and memory: a circular determinism between physiology and behaviour. Progress Neuro-psychopharmacol Biol Psychiatry 21:507–29Google Scholar
  104. Obata T (2006) Tamoxifen protect against hydroxyl radical generation induced by phenelzine in rat striatum. Toxicology 222:46–52PubMedGoogle Scholar
  105. Ohno S, Kawasaki H, Imajoh S, Suzuki K, Inagaki M, Yokokura H, Sakoh T, Hidaka H (1987) Tissue-specific expression of three distinct types of rabbit protein kinase C. Nature 325:161–6PubMedGoogle Scholar
  106. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O (2004) Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 19:89–95PubMedGoogle Scholar
  107. Pandey GN, Ren X, Dwivedi Y, Pavuluri MN (2008) Decreased protein kinase C (PKC) in platelets of pediatric bipolar patients: effect of treatment with mood stabilizing drugs. J Psychiatr Res 42:106–16PubMedCentralPubMedGoogle Scholar
  108. Peet M, Peters S (1995) Drug-induced mania. Drug Saf 12:146–53PubMedGoogle Scholar
  109. Pereira M, Martynhak BJ, Baretta IP, Correia D, Siba IP, Andreatini R (2011) Antimanic-like effect of tamoxifen is not reproduced by acute or chronic administration of medroxyprogesterone or clomiphene. Neurosci Lett 500:95–8PubMedGoogle Scholar
  110. Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ, Henry BL, Zhuang X, Masten VL, Sharp RF, Geyer MA (2009) A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 66:1072–80PubMedCentralPubMedGoogle Scholar
  111. Perry W, Minassian A, Henry B, Kincaid M, Young JW, Geyer MA (2010) Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Res 178:84–91PubMedCentralPubMedGoogle Scholar
  112. Pollack IF, DaRosso RC, Robertson PL, Jakacki RL, Mirro JR Jr, Blatt J, Nicholson S, Packer RJ, Allen JC, Cisneros A, Jordan VC (1997) A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 3:1109–15PubMedGoogle Scholar
  113. Post RM, Weiss SR (1989) Sensitization, kindling, and anticonvulsants in mania. J Clin Psychiatry 50(Suppl):23–30, discussion 45–7PubMedGoogle Scholar
  114. Rajkowska G (2002) Cell pathology in bipolar disorder. Bipolar Disord 4:105–16PubMedGoogle Scholar
  115. Ramakers GM, Pasinelli P, Hens JJ, Gispen WH, De Graan PN (1997) Protein kinase C in synaptic plasticity: changes in the in situ phosphorylation state of identified pre- and postsynaptic substrates. Prog Neuropsychopharmacol Biol Psychiatry 21:455–86PubMedGoogle Scholar
  116. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP (2003) Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 121:109–22PubMedGoogle Scholar
  117. Sabioni P, Baretta IP, Ninomiya EM, Gustafson L, Rodrigues AL, Andreatini R (2008) The antimanic-like effect of tamoxifen: behavioural comparison with other PKC-inhibiting and antiestrogenic drugs. Prog Neuropsychopharmacol Biol Psychiatry 32:1927–31PubMedGoogle Scholar
  118. Schloesser RJ, Huang J, Klein PS, Manji HK (2007) Cellular Plasticity Cascades in the Pathophysiology and Treatment of Bipolar Disorder. Neuropsychopharmacology 33:110–133PubMedGoogle Scholar
  119. Shaldubina A, Einat H, Szechtman H, Shimon H, Belmaker RH (2002) Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm 109:433–40PubMedGoogle Scholar
  120. Smith DF (1981) Central and peripheral effects of lithium on amphetamine-induced hyperactivity in rats. Pharmacol Biochem Behav 14:439–42PubMedGoogle Scholar
  121. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D (2007) Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 9:551–60PubMedGoogle Scholar
  122. Soares JC, Chen G, Dippold CS, Wells KF, Frank E, Kupfer DJ, Manji HK, Mallinger AG (2000) Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: a preliminary study. Psychiatry Res 95:109–18Google Scholar
  123. Stabel S, Parker PJ (1991) Protein kinase C. Pharmacol Ther 51:71–95PubMedGoogle Scholar
  124. Steckert AV, Valvassori SS, Mina F, Lopes-Borges J, Varela RB, Kapczinski F, Dal-Pizzol F, Quevedo J (2012) Protein kinase C and oxidative stress in an animal model of mania. Curr Neurovasc Res 9:47–57PubMedGoogle Scholar
  125. Steketee JD (1993) Injection of the protein kinase inhibitor H7 into the A10 dopamine region blocks the acute responses to cocaine: behavioral and in vivo microdialysis studies. Neuropharmacology 32:1289–97PubMedGoogle Scholar
  126. Steketee JD (1994) Intra-A10 injection of H7 blocks the development of sensitization to cocaine. Neuroreport 6:69–72PubMedGoogle Scholar
  127. Steketee JD (1997) Intra-ventral tegmental area administration of H7 delays, but does not prevent the development of cocaine-induced sensitization. Brain Res Bull 43:565–71PubMedGoogle Scholar
  128. Szabo ST, Machado-Vieira R, Yuan P, Wang Y, Wei Y, Falke C, Cirelli C, Tononi G, Manji HK, Du J (2009) Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology 56:47–55PubMedCentralPubMedGoogle Scholar
  129. Tanaka C, Nishizuka Y (1994) The protein kinase C family for neuronal signaling. Ann Rev Neurosci 17:551–67PubMedGoogle Scholar
  130. Tang P, Roldan G, Brasher PM, Fulton D, Roa W, Murtha A, Cairncross JG, Forsyth PA (2006) A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol 78:311–6PubMedGoogle Scholar
  131. Torres IJ, DeFreitas VG, DeFreitas CM, Kauer-Sant'Anna M, Bond DJ, Honer WG, Lam RW, Yatham LN (2010) Neurocognitive functioning in patients with bipolar I disorder recently recovered from a first manic episode. J Clin Psychiatry 71:1234–42PubMedGoogle Scholar
  132. Totoń E, Ignatowicz E, Skrzeczkowska K, Rybczyńska M (2011) Protein kinase Cε as a cancer marker and target for anticancer therapy. Pharmacol Rep 63:19–29PubMedGoogle Scholar
  133. Tuquet C, Dupont J, Mesneau A, Roussaux J (2000) Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria. Cell Biol Toxicol 16:207–19PubMedGoogle Scholar
  134. Wade GN (1972) Gonadal hormones and behavioral regulation of body weight. Physiol Behav 8:523–34PubMedGoogle Scholar
  135. Walf AA, Frye CA (2006) A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology 31:1097–111PubMedCentralPubMedGoogle Scholar
  136. Wang HY, Friedman E (1989) Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacol (Berl) 99:213–8Google Scholar
  137. Wang HY, Friedman E (1996) Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 40:568–75PubMedGoogle Scholar
  138. Wang HY, Markowitz P, Levinson D, Undie AS, Friedman E (1999) Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. J Psychiatr Res 33:171–9Google Scholar
  139. Wang H, Friedman E (2001) Increased association of brain protein kinase C with the receptor for activated C kinase-1 (RACK1) in bipolar affective disorder. Biol Psychiatry 50:364–70PubMedGoogle Scholar
  140. Watson DG, Lenox RH (1996) Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J Neurochem 67:767–77PubMedGoogle Scholar
  141. Wehr TA (1991) Sleep-loss as a possible mediator of diverse causes of mania. Br J Psychiatry 159:576–8PubMedGoogle Scholar
  142. Wehr TA, Goodwin FK, Wirz-Justice A, Breitmaier J, Craig C (1982) 48-hour sleep-wake cycles in manic-depressive illness: naturalistic observations and sleep deprivation experiments. Arch Gen Psychiatry 39:559–65PubMedGoogle Scholar
  143. Wehr TA, Sack DA, Rosenthal NE (1987) Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 144:201–4PubMedGoogle Scholar
  144. Wu-Zhang AX, Newton AC (2013) Protein kinase C pharmacology: refining the toolbox. Biochem J 452:195–209PubMedGoogle Scholar
  145. Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF (2008) Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 65:255–63PubMedGoogle Scholar
  146. Young JW, Henry BL, Geyer MA (2011) Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol 164:1263–84PubMedGoogle Scholar
  147. Zanin-Zhorov A, Dustin ML, Blazar BR (2011) PKC-θ function at the immunological synapse: prospects for therapeutic targeting. Trends Immunol 32:358–63PubMedCentralPubMedGoogle Scholar
  148. Zarate CA, Manji HK (2009) Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 23:569–82PubMedCentralPubMedGoogle Scholar
  149. Zarate CA Jr, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, Manji HK (2007) Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 9:561–70PubMedGoogle Scholar
  150. Zhang D, Anantharam V, Kanthasamy A, Kanthasamy AG (2007) Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J Pharmacol Exp Ther 322:913–22PubMedGoogle Scholar
  151. Zhao Y, Wang LM, Chaiswing L, Yen HC, Oberley TD, Lien YC, Lin SM, Mattson MP, St Clair D (2006) Tamoxifen protects against acute tumor necrosis factor alpha-induced cardiac injury via improving mitochondrial functions. Free Radic Biol Med 40:1234–41PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Fernanda Armani
    • 1
  • Monica Levy Andersen
    • 1
  • José Carlos Fernandes Galduróz
    • 1
    • 2
  1. 1.Departamento de PsicobiologiaUniversidade Federal de São PauloSão PauloBrazil
  2. 2.São PauloBrazil

Personalised recommendations